# US 7,612,107 B2 · Treatment and inhibition of disease conditions using flexible heteroarotinoids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,612,107 B2
- Document ID: US7612107B2
- Status: Granted
- Kind: B2
- Application number: 11/404,701
- Filed: 2006-04-14
- Published: 2006-11-09
- Granted: 2009-11-03
- Earliest claimed: 2005-04-15
- Assignees: The Board of Regents of the University of Oklahoma
- Inventors: Doris M. Benbrook; Martin Turman; Suresh Guruswamy
- Web page: https://patentgrep.com/patent/US7612107B2

## CPC

- A61K 31/382: having six-membered rings, e.g. thioxanthenes (thiothixene A61K31/496)
- A61K 31/38: having sulfur as a ring hetero atom
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention contemplates methods of treating, reducing, inhibiting or preventing several diseases by the administration of flexible heteroarotinoids. Among the diseases or conditions which can benefit from treatment with flexible heteroarotinoids as described herein are, (1) cancers and other diseases that involve abnormal differentiation, (2) diabetes, (3) hemophilia, (4) liver disease, (5) diseases involving human aldehyde dehydrogenase 2, (6) polycystic kidney disease, (7) lysosomal storage diseases, (8) high cholesterol, (9) obesity, (10) high triglycerides, (11) glycoprotein metabolism diseases, and (12) diseases involving abnormal angiogenesis.

## Claims

### Claim 1

A method for treating or inhibiting polycystic kidney disease in a subject in need of treatment thereof or at risk therefor, comprising:
providing a quantity of a flexible heteroarotinoid having a urea or thiorurea linker wherein the flexible heteroarotinoid is selected from the group consisting of SHetA2, SHetA3, and SHetA4; and
administering to the subject the flexible heteroarotinoid having a urea or thiourea linker.

### Claim 2 (depends on 1)

The method of claim 1 wherein the subject is a mammal.

### Claim 3 (depends on 2)

The method of claim 2 wherein the subject is a human.

### Claim 4 (depends on 1)

The method of claim 1 wherein the flexible heteroarotinoid is provided in a composition comprising a pharmaceutically-acceptable carrier.